<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Hbm Holdings Ltd. — News on 6ix</title>
<link>https://6ix.com/company/hbm-holdings-ltd</link>
<description>Latest news and press releases for Hbm Holdings Ltd. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 09 Mar 2026 08:32:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/hbm-holdings-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683688aa78dffbe2df16b5db.webp</url>
<title>Hbm Holdings Ltd.</title>
<link>https://6ix.com/company/hbm-holdings-ltd</link>
</image>
<item>
<title>Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis</title>
<link>https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-and-kelun-biotech-announce-nmpa-approval-of-ind-application-for-hbm7575skb575-for-the-treatment-of-atopic-dermatitis</link>
<guid isPermaLink="true">https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-and-kelun-biotech-announce-nmpa-approval-of-ind-application-for-hbm7575skb575-for-the-treatment-of-atopic-dermatitis</guid>
<pubDate>Mon, 09 Mar 2026 08:32:00 GMT</pubDate>
<description>Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, and Kelun-Biotech (6990.HK) today announced that the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (IND) application for HBM7575/SKB575, a long-acting bispecific antibody targeting thymic stromal lymphopoietin (TSLP) and an undisclosed target co-developed by the two parties, for</description>
</item>
<item>
<title>Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results</title>
<link>https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-announces-positive-profit-000100283</link>
<guid isPermaLink="true">https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-announces-positive-profit-000100283</guid>
<pubDate>Wed, 04 Feb 2026 00:01:00 GMT</pubDate>
<description>Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a positive profit alert for the year ended December 31, 2025.</description>
</item>
<item>
<title>Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration</title>
<link>https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-acquires-common-stock-in-spruce-biosciences-deepening-strategic-collaboration</link>
<guid isPermaLink="true">https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-acquires-common-stock-in-spruce-biosciences-deepening-strategic-collaboration</guid>
<pubDate>Mon, 19 Jan 2026 00:02:00 GMT</pubDate>
<description>Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (Nasdaq: SPRB) ("Spruce"). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of</description>
</item>
<item>
<title>Control Devices Acquires Sherwood Valve</title>
<link>https://6ix.com/company/hbm-holdings-ltd/news/control-devices-acquires-sherwood-valve</link>
<guid isPermaLink="true">https://6ix.com/company/hbm-holdings-ltd/news/control-devices-acquires-sherwood-valve</guid>
<pubDate>Mon, 12 Jan 2026 13:40:00 GMT</pubDate>
<description>Control Devices, a portfolio company of HBM Holdings, today announced the acquisition of Sherwood Valve. The acquisition expands Control Devices' flow control portfolio and strengthens its position within the compressed gas industry, while further enhancing HBM Holdings' depth of expertise in flow control and engineered products.</description>
</item>
<item>
<title>Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates</title>
<link>https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-enters-into-long-term-strategic-collaboration-with-lannacheng-to-advance-next-generation-radionuclide-drug-conjugates</link>
<guid isPermaLink="true">https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-enters-into-long-term-strategic-collaboration-with-lannacheng-to-advance-next-generation-radionuclide-drug-conjugates</guid>
<pubDate>Mon, 29 Dec 2025 01:58:00 GMT</pubDate>
<description>Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it has entered into a long-term strategic collaboration with Yantai Lannacheng Biotechnology Co., Ltd. ("Lannacheng"). The two parties will leverage their respective resources and strengths to jointly advance the development of next-generation radionuclide drug conjugates (RDCs).</description>
</item>
<item>
<title>Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies</title>
<link>https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-enters-into-global-strategic-collaboration-and-license-agreement-with-bristol-myers-squibb-to-discover-and-develop-next-generation-multi-specific-antibodies</link>
<guid isPermaLink="true">https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-enters-into-global-strategic-collaboration-and-license-agreement-with-bristol-myers-squibb-to-discover-and-develop-next-generation-multi-specific-antibodies</guid>
<pubDate>Wed, 17 Dec 2025 00:04:00 GMT</pubDate>
<description>Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a multi-year, global strategic collaboration and license agreement with Bristol Myers Squibb to discover and develop next-generation multi-specific antibodies.</description>
</item>
<item>
<title>Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology</title>
<link>https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-advances-global-strategic-collaboration-with-astrazeneca-to-discover-and-develop-next-generation-biotherapeutics-in-oncology</link>
<guid isPermaLink="true">https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-advances-global-strategic-collaboration-with-astrazeneca-to-discover-and-develop-next-generation-biotherapeutics-in-oncology</guid>
<pubDate>Mon, 24 Nov 2025 00:01:00 GMT</pubDate>
<description>Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics for immunology and oncology, today announced an update and advancement of its global strategic collaboration with AstraZeneca, originally established in March 2025. The collaboration aims to discover and develop next-generation biotherapeutics, including antibody-drug conjugates (ADCs) and T cell engagers, leveraging the knowledge of b</description>
</item>
<item>
<title>Harbour BioMed and Evinova China Announce Strategic AI Collaboration to Accelerate AI-Enabled Drug Development</title>
<link>https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-and-evinova-china-announce-strategic-ai-collaboration-to-accelerate-ai-enabled-drug-development</link>
<guid isPermaLink="true">https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-and-evinova-china-announce-strategic-ai-collaboration-to-accelerate-ai-enabled-drug-development</guid>
<pubDate>Fri, 07 Nov 2025 06:00:00 GMT</pubDate>
<description>Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, and Evinova, a global health-tech company accelerating the delivery of better health outcomes by propelling the life sciences sector forward in digital health, announced a strategic collaboration in artificial intelligence (AI).</description>
</item>
<item>
<title>Harbour BioMed Launches First Fully Human Generative AI HCAb Model to Accelerate Next-Generation Biologics Discovery</title>
<link>https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-launches-first-fully-human-generative-ai-hcab-model-to-accelerate-next-generation-biologics-discovery</link>
<guid isPermaLink="true">https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-launches-first-fully-human-generative-ai-hcab-model-to-accelerate-next-generation-biologics-discovery</guid>
<pubDate>Tue, 28 Oct 2025 14:07:00 GMT</pubDate>
<description>Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced the launch of its first fully human Generative AI HCAb (Heavy Chain-Only Antibody) Model powered by its Hu-mAtrIx™ AI platform, built upon the Harbour Mice® platform. This platform establishes a closed-loop process integrating AI design, intelligent screening, and wet-lab validation.</description>
</item>
<item>
<title>Harbour BioMed Announces Positive Phase II Results for HBM4003 and Tislelizumab Combination in MSS mCRC</title>
<link>https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-announces-positive-phase-ii-results-for-hbm4003-and-tislelizumab-combination-in-mss-mcrc</link>
<guid isPermaLink="true">https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-announces-positive-phase-ii-results-for-hbm4003-and-tislelizumab-combination-in-mss-mcrc</guid>
<pubDate>Thu, 23 Oct 2025 00:00:00 GMT</pubDate>
<description>Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced positive Phase II clinical data for porustobart (HBM4003), a next-generation, fully human heavy-chain-only anti-CTLA-4 antibody, in combination with tislelizumab, in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC).</description>
</item>
<item>
<title>Harbour BioMed Reports 2025 Interim Results</title>
<link>https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-reports-2025-interim-results</link>
<guid isPermaLink="true">https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-reports-2025-interim-results</guid>
<pubDate>Wed, 27 Aug 2025 14:40:00 GMT</pubDate>
<description>Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced its interim results for the six months ended June 30, 2025.</description>
</item>
<item>
<title>Harbour BioMed Appoints Yajie Li as Chief Medical Officer</title>
<link>https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-appoints-yajie-li-as-chief-medical-officer</link>
<guid isPermaLink="true">https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-appoints-yajie-li-as-chief-medical-officer</guid>
<pubDate>Mon, 25 Aug 2025 01:00:00 GMT</pubDate>
<description>Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced the appointment of Yajie Li as Chief Medical Officer (CMO). Ms. Li will be based in Shanghai and report directly to Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer of Harbour BioMed.</description>
</item>
<item>
<title>Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025</title>
<link>https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-to-present-phase-ii-data-of-hbm4003-and-tislelizumab-combination-in-mss-metastatic-colorectal-cancer-at-esmo-2025</link>
<guid isPermaLink="true">https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-to-present-phase-ii-data-of-hbm4003-and-tislelizumab-combination-in-mss-metastatic-colorectal-cancer-at-esmo-2025</guid>
<pubDate>Wed, 30 Jul 2025 00:01:00 GMT</pubDate>
<description>Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it will present Phase II clinical data on its next-generation, fully human heavy-chain-only anti-CTLA-4 antibody, porustobart (HBM4003), in combination with tislelizumab, for the treatment of microsatellite stable (MSS) metastatic colorectal cancer (mCRC), at the ESMO Congress 2025, taking place October 17-21, 20</description>
</item>
<item>
<title>Harbour BioMed Announces Positive Profit Alert for 2025 Interim Results</title>
<link>https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-announces-positive-profit-alert-for-2025-interim-results</link>
<guid isPermaLink="true">https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-announces-positive-profit-alert-for-2025-interim-results</guid>
<pubDate>Mon, 28 Jul 2025 00:11:00 GMT</pubDate>
<description>Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a positive profit alert for the six months ended June 30, 2025 (the "Reporting Period").</description>
</item>
<item>
<title>HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma</title>
<link>https://6ix.com/company/hbm-holdings-ltd/news/hbm9378win378-a-long-acting-fully-human-anti-tslp-antibody-enters-global-phase-2-polaris-trial-for-asthma</link>
<guid isPermaLink="true">https://6ix.com/company/hbm-holdings-ltd/news/hbm9378win378-a-long-acting-fully-human-anti-tslp-antibody-enters-global-phase-2-polaris-trial-for-asthma</guid>
<pubDate>Wed, 23 Jul 2025 12:36:00 GMT</pubDate>
<description>Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that its partner, Windward Bio AG ("Windward Bio"), has initiated the POLARIS clinical study, a global, randomized, double-blind, placebo-controlled Phase 2 study evaluating the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma. Initial data are expected in mid-2026.</description>
</item>
<item>
<title>Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers</title>
<link>https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-enters-global-strategic-collaboration-with-otsuka-to-advance-bcmaxcd3-bispecific-t-cell-engagers</link>
<guid isPermaLink="true">https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-enters-global-strategic-collaboration-with-otsuka-to-advance-bcmaxcd3-bispecific-t-cell-engagers</guid>
<pubDate>Mon, 23 Jun 2025 00:03:00 GMT</pubDate>
<description>Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a global strategic collaboration with Otsuka Pharmaceutical Co., Ltd. ("Otsuka") to advance BCMAxCD3 bispecific T-cell engagers for the treatment of autoimmune diseases.</description>
</item>
<item>
<title>China National Intellectual Property Administration Affirms Validity of Harbour BioMed's Patent; Infringement Lawsuit Moves Forward</title>
<link>https://6ix.com/company/hbm-holdings-ltd/news/china-national-intellectual-property-administration-affirms-validity-of-harbour-biomeds-patent-infringement-lawsuit-moves-forward</link>
<guid isPermaLink="true">https://6ix.com/company/hbm-holdings-ltd/news/china-national-intellectual-property-administration-affirms-validity-of-harbour-biomeds-patent-infringement-lawsuit-moves-forward</guid>
<pubDate>Mon, 16 Jun 2025 12:33:00 GMT</pubDate>
<description>Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology and oncology, today announced key developments in its intellectual property (IP) protection efforts. Following an invalidation request filed by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") against Harbour BioMed's patent entitled "Binding Molecule" (Patent Application No. CN201210057668.0, the "HCAb Patent"), the China</description>
</item>
<item>
<title>Harbour BioMed Appoints Youchen Chen as Chief Financial Officer</title>
<link>https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-appoints-youchen-chen-as-chief-financial-officer</link>
<guid isPermaLink="true">https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-appoints-youchen-chen-as-chief-financial-officer</guid>
<pubDate>Thu, 10 Apr 2025 02:00:00 GMT</pubDate>
<description>Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology and oncology, today announced the appointment of Youchen (YC) Chen as Chief Financial Officer. YC will be based in Shanghai and Hong Kong SAR, and report directly to Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed.</description>
</item>
<item>
<title>Harbour BioMed Reports Full Year 2024 Financial Results</title>
<link>https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-reports-full-year-2024-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-reports-full-year-2024-financial-results</guid>
<pubDate>Mon, 31 Mar 2025 10:13:00 GMT</pubDate>
<description>Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced its financial results for the year ended December 31, 2024.</description>
</item>
<item>
<title>Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Therapeutic Antibodies</title>
<link>https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-enters-into-global-strategic-collaboration-with-astrazeneca-to-discover-and-develop-next-generation-therapeutic-antibodies</link>
<guid isPermaLink="true">https://6ix.com/company/hbm-holdings-ltd/news/harbour-biomed-enters-into-global-strategic-collaboration-with-astrazeneca-to-discover-and-develop-next-generation-therapeutic-antibodies</guid>
<pubDate>Fri, 21 Mar 2025 11:21:00 GMT</pubDate>
<description>Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in immunology and oncology, today announced a global strategic collaboration with AstraZeneca to discover and develop next-generation multi-specific antibodies for immunology, oncology and beyond. The strategic collaboration includes an option to license multiple programs utilizing Harbour BioMed's proprietary Harbour Mice® fully human anti</description>
</item>
</channel>
</rss>